Systemic sclerosis & Raynaud's
Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration
Authors' conclusion
IVIG seems to be a promising therapeutic option for the management of GI symptoms in SSc, including IPO.
Study context
- Population
- Patients with SSc-myositis overlap with gastrointestinal (GI) symptoms, including intestinal pseudo-obstruction (IPO)
- Participants
- 3 cases
- Outcome
- Response of GI symptoms after IVIG administration
Methodological detailsPRISMA 2020 guideline
- PRISMA 2020 guideline
Main finding
As reported in the abstract
GI symptoms, including IPO
- Remarkable and rapid improvement of GI symptoms, including IPO, after IVIG
Observational data: associations, not effects.
Further findings
Systematic literature review: efficacy and safety of IVIG against GI manifestations of SSc
- Previous reports support efficacy and safety of IVIG; all retrospective, lacking short-term outcomes with objective quantitative metrics
Original publication
Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration. Rheumatology (Oxford). Published 24 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →